Cargando…

Investigation of the natural supplement IQP-AS-119 for the prevention of upper respiratory tract infections in marathon race participants: A randomized, double-blind, placebo-controlled pilot study

Intense and prolonged exercise leads to immune suppression, causing upper respiratory tract infections (URTI). A proprietary standardized dietary supplement, IQP-AS-119 has been previously developed to aid immune responses under such conditions. The current randomized, double-blind, placebo-controll...

Descripción completa

Detalles Bibliográficos
Autores principales: Bongartz, Udo, Hochmann, Uwe, Pohl, Ute, Bothe, Gordana, Costa, Patricia De, Chong, Pee-Win, Chew, Lynette, Uebelhack, Ralf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791916/
https://www.ncbi.nlm.nih.gov/pubmed/33456511
http://dx.doi.org/10.3892/etm.2020.9575
_version_ 1783633694559305728
author Bongartz, Udo
Hochmann, Uwe
Pohl, Ute
Bothe, Gordana
Costa, Patricia De
Chong, Pee-Win
Chew, Lynette
Uebelhack, Ralf
author_facet Bongartz, Udo
Hochmann, Uwe
Pohl, Ute
Bothe, Gordana
Costa, Patricia De
Chong, Pee-Win
Chew, Lynette
Uebelhack, Ralf
author_sort Bongartz, Udo
collection PubMed
description Intense and prolonged exercise leads to immune suppression, causing upper respiratory tract infections (URTI). A proprietary standardized dietary supplement, IQP-AS-119 has been previously developed to aid immune responses under such conditions. The current randomized, double-blind, placebo-controlled pilot study aimed to investigate the effects of IQP-AS-119 on marathon runners. A total of 80 participants were randomized equally into groups receiving either placebo (P group) or IQP-AS-119 (V group) treatment, starting 3 weeks before and for 14 days after the marathon. Benefit assessment was performed using different questionnaires. Post-marathon, the V and P groups reported 1±2.38 and 2.11±3.25 days with upper respiratory tract symptoms (URTS), respectively (P=0.038). During the 14 days post-marathon, 20.0% of the participants in the V group compared with 44.4% in the P group reported URTS (P=0.042). The V group reported significantly milder URTS compared with the P group on Days 9, 12, 13 and 14 post-marathon (P<0.05). The total Perceived Stress Questionnaire-20 score on days 2-14 were significantly lower for the V group compared with the P group (P=0.035). In the Short Form 12 Health Survey, the V group exhibited significant improvement in mental composite score on days -5 to 14 compared with the P group (P=0.038). In the overall treatment effect assessment, there were no statistically significant differences between the groups. The IQP-AS-119 was rated ‘very good’ or ‘good’ by investigators and participants, respectively, for 71 and 65% of the participants. The tolerability of IQP-AS-119 was rated as ‘very good’ or ‘good’ by both investigators and 95% of participants. No clinically relevant differences were observed between groups regarding adverse events or other safety parameters. Therefore, IQP-AS-119 was demonstrated to reduce the incidence and severity of URTI in marathon runners. Given its good tolerability profile, IQP-AS-119 may be a good nutritional supplement for the reduction of URTS in susceptible individuals.
format Online
Article
Text
id pubmed-7791916
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-77919162021-01-14 Investigation of the natural supplement IQP-AS-119 for the prevention of upper respiratory tract infections in marathon race participants: A randomized, double-blind, placebo-controlled pilot study Bongartz, Udo Hochmann, Uwe Pohl, Ute Bothe, Gordana Costa, Patricia De Chong, Pee-Win Chew, Lynette Uebelhack, Ralf Exp Ther Med Articles Intense and prolonged exercise leads to immune suppression, causing upper respiratory tract infections (URTI). A proprietary standardized dietary supplement, IQP-AS-119 has been previously developed to aid immune responses under such conditions. The current randomized, double-blind, placebo-controlled pilot study aimed to investigate the effects of IQP-AS-119 on marathon runners. A total of 80 participants were randomized equally into groups receiving either placebo (P group) or IQP-AS-119 (V group) treatment, starting 3 weeks before and for 14 days after the marathon. Benefit assessment was performed using different questionnaires. Post-marathon, the V and P groups reported 1±2.38 and 2.11±3.25 days with upper respiratory tract symptoms (URTS), respectively (P=0.038). During the 14 days post-marathon, 20.0% of the participants in the V group compared with 44.4% in the P group reported URTS (P=0.042). The V group reported significantly milder URTS compared with the P group on Days 9, 12, 13 and 14 post-marathon (P<0.05). The total Perceived Stress Questionnaire-20 score on days 2-14 were significantly lower for the V group compared with the P group (P=0.035). In the Short Form 12 Health Survey, the V group exhibited significant improvement in mental composite score on days -5 to 14 compared with the P group (P=0.038). In the overall treatment effect assessment, there were no statistically significant differences between the groups. The IQP-AS-119 was rated ‘very good’ or ‘good’ by investigators and participants, respectively, for 71 and 65% of the participants. The tolerability of IQP-AS-119 was rated as ‘very good’ or ‘good’ by both investigators and 95% of participants. No clinically relevant differences were observed between groups regarding adverse events or other safety parameters. Therefore, IQP-AS-119 was demonstrated to reduce the incidence and severity of URTI in marathon runners. Given its good tolerability profile, IQP-AS-119 may be a good nutritional supplement for the reduction of URTS in susceptible individuals. D.A. Spandidos 2021-02 2020-12-16 /pmc/articles/PMC7791916/ /pubmed/33456511 http://dx.doi.org/10.3892/etm.2020.9575 Text en Copyright: © Bongartz et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Bongartz, Udo
Hochmann, Uwe
Pohl, Ute
Bothe, Gordana
Costa, Patricia De
Chong, Pee-Win
Chew, Lynette
Uebelhack, Ralf
Investigation of the natural supplement IQP-AS-119 for the prevention of upper respiratory tract infections in marathon race participants: A randomized, double-blind, placebo-controlled pilot study
title Investigation of the natural supplement IQP-AS-119 for the prevention of upper respiratory tract infections in marathon race participants: A randomized, double-blind, placebo-controlled pilot study
title_full Investigation of the natural supplement IQP-AS-119 for the prevention of upper respiratory tract infections in marathon race participants: A randomized, double-blind, placebo-controlled pilot study
title_fullStr Investigation of the natural supplement IQP-AS-119 for the prevention of upper respiratory tract infections in marathon race participants: A randomized, double-blind, placebo-controlled pilot study
title_full_unstemmed Investigation of the natural supplement IQP-AS-119 for the prevention of upper respiratory tract infections in marathon race participants: A randomized, double-blind, placebo-controlled pilot study
title_short Investigation of the natural supplement IQP-AS-119 for the prevention of upper respiratory tract infections in marathon race participants: A randomized, double-blind, placebo-controlled pilot study
title_sort investigation of the natural supplement iqp-as-119 for the prevention of upper respiratory tract infections in marathon race participants: a randomized, double-blind, placebo-controlled pilot study
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791916/
https://www.ncbi.nlm.nih.gov/pubmed/33456511
http://dx.doi.org/10.3892/etm.2020.9575
work_keys_str_mv AT bongartzudo investigationofthenaturalsupplementiqpas119forthepreventionofupperrespiratorytractinfectionsinmarathonraceparticipantsarandomizeddoubleblindplacebocontrolledpilotstudy
AT hochmannuwe investigationofthenaturalsupplementiqpas119forthepreventionofupperrespiratorytractinfectionsinmarathonraceparticipantsarandomizeddoubleblindplacebocontrolledpilotstudy
AT pohlute investigationofthenaturalsupplementiqpas119forthepreventionofupperrespiratorytractinfectionsinmarathonraceparticipantsarandomizeddoubleblindplacebocontrolledpilotstudy
AT bothegordana investigationofthenaturalsupplementiqpas119forthepreventionofupperrespiratorytractinfectionsinmarathonraceparticipantsarandomizeddoubleblindplacebocontrolledpilotstudy
AT costapatriciade investigationofthenaturalsupplementiqpas119forthepreventionofupperrespiratorytractinfectionsinmarathonraceparticipantsarandomizeddoubleblindplacebocontrolledpilotstudy
AT chongpeewin investigationofthenaturalsupplementiqpas119forthepreventionofupperrespiratorytractinfectionsinmarathonraceparticipantsarandomizeddoubleblindplacebocontrolledpilotstudy
AT chewlynette investigationofthenaturalsupplementiqpas119forthepreventionofupperrespiratorytractinfectionsinmarathonraceparticipantsarandomizeddoubleblindplacebocontrolledpilotstudy
AT uebelhackralf investigationofthenaturalsupplementiqpas119forthepreventionofupperrespiratorytractinfectionsinmarathonraceparticipantsarandomizeddoubleblindplacebocontrolledpilotstudy